{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:34:01Z","timestamp":1788186841350,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to assess clinical, treatment, and prognostic features in patients with brain metastases (BM) from solid tumors achieving long-term survival (LTS). Further, the accuracy of diagnosis-specific Graded Prognostic Assessment scores (ds-GPA) to predict LTS was evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients admitted for radiotherapy of BM between 2010 and 2020 at a\u00a0large tertiary cancer center with survival of at least 3\u00a0years from diagnosis of BM were included. Patient, tumor, treatment characteristics and ds-GPA were compiled retrospectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From a\u00a0total of 1248\u00a0patients with BM, 61 (4.9%) survived \u2265\u202f3\u00a0years. In 40\u00a0patients, detailed patient charts were available. Among LTS patients, median survival time from diagnosis of BM was 51.5\u00a0months. Most frequent primary tumors were lung cancer (45%), melanoma (20%), and breast cancer (17.5%). At the time of diagnosis of BM, 11\/40\u00a0patients (27.5%) had oligometastatic disease. Estimated mean survival time based on ds-GPA was 19.7\u00a0months (in 8\u00a0cases estimated survival &lt;\u202f12\u00a0months). Resection followed by focal or whole-brain radiotherapy (WBRT) was often applied (60%), followed by primary stereotactic radiotherapy (SRT) (20%) or WBRT (20%). 80% of patients received systemic treatment, appearing particularly active in specifically altered non-small lung cancer (NSCLC), melanoma, and HER2-positive breast cancer. Karnofsky performance score (KPS) and the presence of oligometastatic disease at BM diagnosis were persisting prognostic factors in LTS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this monocentric setting reflecting daily pattern of care, LTS with BM is heterogeneous and difficult to predict. Effective local treatment and modern systemic therapies often appear crucial for LTS. The impact of concomitant diseases and frailty is not clear.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02123-4","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:03:14Z","timestamp":1693400594000},"page":"335-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term survival in patients with brain metastases\u2014clinical characterization of a\u00a0rare scenario"],"prefix":"10.1007","volume":"200","author":[{"given":"M.","family":"H\u00fcgel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kuhnt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"N\u00e4gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Papsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Klagges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hambsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"G\u00fcresir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-5089","authenticated-orcid":false,"given":"C.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"2123_CR1","doi-asserted-by":"publisher","unstructured":"Li AY, Gaebe K, Jerzak KJ, Cheema PK, Sahgal A, Das S (2022) Intracranial Metastatic Disease: Present Challenges, Future Opportunities. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.855182. eCollection 2022","DOI":"10.3389\/fonc.2022.855182"},{"key":"2123_CR2","doi-asserted-by":"publisher","first-page":"vdaa178","DOI":"10.1093\/noajnl\/vdaa178","volume":"3","author":"S Habbous","year":"2020","unstructured":"Habbous\u00a0S, Forster\u00a0K, Darling\u00a0G, Jerzak\u00a0K, Holloway\u00a0CMB, Sahgal\u00a0A, Das\u00a0S (2020) Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a\u00a0population-based study. Neuro-oncol Adv 3:vdaa178. https:\/\/doi.org\/10.1093\/noajnl\/vdaa178","journal-title":"Neuro-oncol Adv"},{"key":"2123_CR3","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney\u00a0DN, Martin\u00a0AM, Catalano\u00a0PJ, Redig\u00a0AJ, Lin\u00a0NU, Lee\u00a0EQ, Wen\u00a0PY, Dunn\u00a0IF, Bi\u00a0WL, Weiss\u00a0SE, Haas-Kogan\u00a0DA, Alexander\u00a0BM, Aizer\u00a0AA (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a\u00a0population-based study. Neuro-Oncol 19:1511\u20131521. https:\/\/doi.org\/10.1093\/neuonc\/nox077","journal-title":"Neuro-Oncol"},{"key":"2123_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00415-002-0870-6","volume":"249","author":"R Soffietti","year":"2002","unstructured":"Soffietti\u00a0R, Rud\u0101\u00a0R, Mutani\u00a0R (2002) Management of brain metastases. J\u00a0Neurol 249:1357\u20131369. https:\/\/doi.org\/10.1007\/s00415-002-0870-6","journal-title":"J Neurol"},{"key":"2123_CR5","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1002\/cncr.10541","volume":"94","author":"LJ Schouten","year":"2002","unstructured":"Schouten\u00a0LJ, Rutten\u00a0J, Huveneers\u00a0HAM, Twijnstra\u00a0A (2002) Incidence of brain metastases in a\u00a0cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698\u20132705. https:\/\/doi.org\/10.1002\/cncr.10541","journal-title":"Cancer"},{"key":"2123_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.radonc.2011.08.041","volume":"102","author":"S Scoccianti","year":"2012","unstructured":"Scoccianti\u00a0S, Ricardi\u00a0U (2012) Treatment of brain metastases: Review of phase III randomized controlled trials. Radiother Oncol 102:168\u2013179. https:\/\/doi.org\/10.1016\/j.radonc.2011.08.041","journal-title":"Radiother Oncol"},{"key":"2123_CR7","unstructured":"Wen Jay Loeffler PYMDSMD (1999) Oncology. Manag Brain Metastases 13(7):941\u2013954, 957\u2013961; discussion 961\u2013962, 9"},{"key":"2123_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/neuonc\/now127","volume":"18","author":"ND Arvold","year":"2016","unstructured":"Arvold\u00a0ND, Lee\u00a0EQ, Mehta\u00a0MP, Margolin\u00a0K, Alexander\u00a0BM, Lin\u00a0NU, Anders\u00a0CK, Soffietti\u00a0R, Camidge\u00a0DR, Vogelbaum\u00a0MA, Dunn\u00a0IF, Wen\u00a0PY (2016) Updates in the management of brain metastases. Neuro-Oncol 18:1043\u20131065. https:\/\/doi.org\/10.1093\/neuonc\/now127","journal-title":"Neuro-Oncol"},{"key":"2123_CR9","first-page":"4655","volume":"32","author":"E Tabouret","year":"2012","unstructured":"Tabouret\u00a0E, Chinot\u00a0O, Metellus\u00a0P, Tallet\u00a0A, Viens\u00a0P, Gon\u00e7alves\u00a0A (2012) Recent Trends in Epidemiology of Brain Metastases: An Overview. Anticancer Res 32:4655\u20134662","journal-title":"Anticancer Res"},{"key":"2123_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rpor.2011.01.002","volume":"16","author":"M Niemiec","year":"2011","unstructured":"Niemiec\u00a0M, G\u0142ogowski\u00a0M, Tyc-Szczepaniak\u00a0D, Wierzchowski\u00a0M, K\u0119pka\u00a0L (2011) Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 16:49\u201353. https:\/\/doi.org\/10.1016\/j.rpor.2011.01.002","journal-title":"Rep Pract Oncol Radiother"},{"key":"2123_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1470-7330-14-8","volume":"14","author":"R Zakaria","year":"2014","unstructured":"Zakaria\u00a0R, Das\u00a0K, Bhojak\u00a0M, Radon\u00a0M, Walker\u00a0C, Jenkinson\u00a0MD (2014) The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis. Cancer Imaging 14:8. https:\/\/doi.org\/10.1186\/1470-7330-14-8","journal-title":"Cancer Imaging"},{"key":"2123_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/sj.bjc.6605373","volume":"101","author":"KE Smedby","year":"2009","unstructured":"Smedby\u00a0KE, Brandt\u00a0L, B\u00e4cklund\u00a0ML, Blomqvist\u00a0P (2009) Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101:1919\u20131924. https:\/\/doi.org\/10.1038\/sj.bjc.6605373","journal-title":"Br J Cancer"},{"key":"2123_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00066-022-01996-1","volume":"198","author":"T Welzel","year":"2022","unstructured":"Welzel\u00a0T, El Shafie\u00a0RA, v. Nettelbladt\u00a0B, Bernhardt\u00a0D, Rieken\u00a0S, Debus\u00a0J (2022) Stereotactic radiotherapy of brain metastases: clinical impact of three-dimensional SPACE imaging for 3T-MRI-based treatment planning. Strahlenther Onkol 198:926\u2013933. https:\/\/doi.org\/10.1007\/s00066-022-01996-1","journal-title":"Strahlenther Onkol"},{"key":"2123_CR14","doi-asserted-by":"publisher","DOI":"10.21037\/cco-21-121","author":"C Ye","year":"2022","unstructured":"Ye\u00a0C, Handa\u00a0P, Sahgal\u00a0A, Lo\u00a0S, Vellayappan\u00a0B (2022) Risk-reduction strategies for late complications arising from brain metastases treated with radiotherapy: a\u00a0narrative review. Chin Clin Oncol. https:\/\/doi.org\/10.21037\/cco-21-121","journal-title":"Chin Clin Oncol"},{"key":"2123_CR15","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/cncr.25707","volume":"117","author":"C Nieder","year":"2011","unstructured":"Nieder\u00a0C, Spanne\u00a0O, Mehta\u00a0MP, Grosu\u00a0AL, Geinitz\u00a0H (2011) Presentation, patterns of care, and survival in patients with brain metastases. Cancer 117:2505\u20132512. https:\/\/doi.org\/10.1002\/cncr.25707","journal-title":"Cancer"},{"key":"2123_CR16","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto\u00a0PW, Mesko\u00a0S, Li\u00a0J, Cagney\u00a0D, Aizer\u00a0A, Lin\u00a0NU, Nesbit\u00a0E, Kruser\u00a0TJ, Chan\u00a0J, Braunstein\u00a0S, Lee\u00a0J, Kirkpatrick\u00a0JP, Breen\u00a0W, Brown\u00a0PD, Shi\u00a0D, Shih\u00a0HA, Soliman\u00a0H, Sahgal\u00a0A, Shanley\u00a0R, Sperduto\u00a0WA, Lou\u00a0E, Everett\u00a0A, Boggs\u00a0DH, Masucci\u00a0L, Roberge\u00a0D, Remick\u00a0J, Plichta\u00a0K, Buatti\u00a0JM, Jain\u00a0S, Gaspar\u00a0LE, Wu\u00a0C\u2011C, Wang\u00a0TJC, Bryant\u00a0J, Chuong\u00a0M, An\u00a0Y, Chiang\u00a0V, Nakano\u00a0T, Aoyama\u00a0H, Mehta\u00a0MP (2020) J Clin Oncol Off J Am Soc Clin Oncol. Surviv Patients With Brain Metastases: Summ Rep Updat Diagnosis-specific Graded Progn Assess Defin Eligibility Quotient 38:3773\u20133784. https:\/\/doi.org\/10.1200\/JCO.20.01255","journal-title":"Surviv Patients With Brain Metastases: Summ Rep Updat Diagnosis-specific Graded Progn Assess Defin Eligibility Quotient"},{"key":"2123_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto\u00a0PW, Kased\u00a0N, Roberge\u00a0D, Xu\u00a0Z, Shanley\u00a0R, Luo\u00a0X, Sneed\u00a0PK, Chao\u00a0ST, Weil\u00a0RJ, Suh\u00a0J, Bhatt\u00a0A, Jensen\u00a0AW, Brown\u00a0PD, Shih\u00a0HA, Kirkpatrick\u00a0J, Gaspar\u00a0LE, Fiveash\u00a0JB, Chiang\u00a0V, Knisely\u00a0JPS, Sperduto\u00a0CM, Lin\u00a0N, Mehta\u00a0M (2012) Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. J\u00a0Clin Oncol 30:419\u2013425. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527","journal-title":"J Clin Oncol"},{"key":"2123_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-002-0354-1","volume":"128","author":"J Lutterbach","year":"2002","unstructured":"Lutterbach\u00a0J, Bartelt\u00a0S, Ostertag\u00a0C (2002) Long-term survival in patients with brain metastases. J\u00a0Cancer Res Clin Oncol 128:417\u2013425. https:\/\/doi.org\/10.1007\/s00432-002-0354-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"2123_CR19","doi-asserted-by":"publisher","first-page":"e000024","DOI":"10.1136\/esmoopen-2015-000024","volume":"1","author":"AS Berghoff","year":"2016","unstructured":"Berghoff\u00a0AS, Schur\u00a0S, F\u00fcreder\u00a0LM, Gatterbauer\u00a0B, Dieckmann\u00a0K, Widhalm\u00a0G, Hainfellner\u00a0J, Zielinski\u00a0CC, Birner\u00a0P, Bartsch\u00a0R, Preusser\u00a0M (2016) Descriptive statistical analysis of a\u00a0real life cohort of 2419\u00a0patients with brain metastases of solid cancers. Esmo Open 1:e24. https:\/\/doi.org\/10.1136\/esmoopen-2015-000024","journal-title":"Esmo Open"},{"key":"2123_CR20","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan\u00a0JS, Sloan\u00a0AE, Davis\u00a0FG, Vigneau\u00a0FD, Lai\u00a0P, Sawaya\u00a0RE (2004) Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J\u00a0Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"2123_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak\u00a0L, Lee\u00a0EQ, Wen\u00a0PY (2012) Epidemiology of Brain Metastases. Curr Oncol Rep 14:48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y","journal-title":"Curr Oncol Rep"},{"key":"2123_CR22","series-title":"Ont","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/curroncol28010054","volume-title":"Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. Curr Oncol Tor","author":"A Dasgupta","year":"2021","unstructured":"Dasgupta\u00a0A, Co\u00a0J, Winter\u00a0J, Millar\u00a0B\u2011A, Laperriere\u00a0N, Tsang\u00a0DS, van Prooijen\u00a0M, Damyanovich\u00a0A, Heaton\u00a0R, Coolens\u00a0C, Bernstein\u00a0M, Kongkham\u00a0P, Zadeh\u00a0G, Berlin\u00a0A, Conrad\u00a0T, Moraes\u00a0FY, Shultz\u00a0DB (2021) Clinicopathologic and Treatment Features of Long-Term Surviving Brain Metastasis Patients. Curr Oncol Tor. Ont, vol 28, pp 549\u2013559 https:\/\/doi.org\/10.3390\/curroncol28010054"},{"key":"2123_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","volume":"70","author":"PW Sperduto","year":"2008","unstructured":"Sperduto\u00a0PW, Berkey\u00a0B, Gaspar\u00a0LE, Mehta\u00a0M, Curran\u00a0W (2008) A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960\u00a0Patients in the RTOG Database. Int J Radiat Oncol 70:510\u2013514. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.06.074","journal-title":"Int J Radiat Oncol"},{"key":"2123_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto\u00a0PW, Chao\u00a0ST, Sneed\u00a0PK, Luo\u00a0X, Suh\u00a0J, Roberge\u00a0D, Bhatt\u00a0A, Jensen\u00a0AW, Brown\u00a0PD, Shih\u00a0H, Kirkpatrick\u00a0J, Schwer\u00a0A, Gaspar\u00a0LE, Fiveash\u00a0JB, Chiang\u00a0V, Knisely\u00a0J, Sperduto\u00a0CM, Mehta\u00a0M (2010) Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259\u00a0Patients. Int J Radiat Oncol 77:655\u2013661. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.025","journal-title":"Int J Radiat Oncol"},{"key":"2123_CR25","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.ijrobp.2011.02.027","volume":"82","author":"PW Sperduto","year":"2012","unstructured":"Sperduto\u00a0PW, Kased\u00a0N, Roberge\u00a0D, Xu\u00a0Z, Shanley\u00a0R, Luo\u00a0X, Sneed\u00a0PK, Chao\u00a0ST, Weil\u00a0RJ, Suh\u00a0J, Bhatt\u00a0A, Jensen\u00a0AW, Brown\u00a0PD, Shih\u00a0HA, Kirkpatrick\u00a0J, Gaspar\u00a0LE, Fiveash\u00a0JB, Chiang\u00a0V, Knisely\u00a0JPS, Sperduto\u00a0CM, Lin\u00a0N, Mehta\u00a0M (2012) Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. Int J Radiat Oncol 82:2111\u20132117. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.027","journal-title":"Int J Radiat Oncol"},{"key":"2123_CR26","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1186\/s12885-020-07459-z","volume":"20","author":"A Bleckmann","year":"2020","unstructured":"Bleckmann\u00a0A, Kirchner\u00a0B, Nietert\u00a0M, Peeck\u00a0M, Balkenhol\u00a0M, Egert\u00a0D, Rohde\u00a0TV, Bei\u00dfbarth\u00a0T, Pukrop\u00a0T (2020) Impact of pre-OP independence in patients with limited brain metastases on long-term survival. Bmc Cancer 20:973. https:\/\/doi.org\/10.1186\/s12885-020-07459-z","journal-title":"Bmc Cancer"},{"key":"2123_CR27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/neuonc\/noab285","volume":"24","author":"N Lamba","year":"2022","unstructured":"Lamba\u00a0N, Catalano\u00a0PJ, Bi\u00a0WL, Wen\u00a0PY, Haas-Kogan\u00a0DA, Cagney\u00a0DN, Aizer\u00a0AA (2022) Predictors of long-term survival among patients with brain metastases. Neuro-Oncol 24:494\u2013496. https:\/\/doi.org\/10.1093\/neuonc\/noab285","journal-title":"Neuro-Oncol"},{"key":"2123_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00066-022-01991-6","volume":"198","author":"S Rogers","year":"2022","unstructured":"Rogers\u00a0S, Baumert\u00a0B, Blanck\u00a0O, B\u00f6hmer\u00a0D, Bostr\u00f6m\u00a0J, Engenhart-Cabillic\u00a0R, Ermis\u00a0E, Exner\u00a0S, Guckenberger\u00a0M, Habermehl\u00a0D, Hemmatazad\u00a0H, Henke\u00a0G, Lohaus\u00a0F, Lux\u00a0S, Mai\u00a0S, Minasch\u00a0D, Rezazadeh\u00a0A, Steffal\u00a0C, Temming\u00a0S, Wittig\u00a0A, Zweifel\u00a0C, Riesterer\u00a0O, Combs\u00a0SE (2022) Stereotactic radiosurgery and radiotherapy for resected brain metastases: current pattern of care in the Radiosurgery and Stereotactic Radiotherapy Working Group of the German Association for Radiation Oncology (DEGRO). Strahlenther Onkol 198:919\u2013925. https:\/\/doi.org\/10.1007\/s00066-022-01991-6","journal-title":"Strahlenther Onkol"},{"key":"2123_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1227\/NEU.0b013e31827fcd60","volume":"72","author":"JH Gans","year":"2013","unstructured":"Gans\u00a0JH, Raper\u00a0DMS, Shah\u00a0AH, Bregy\u00a0A, Heros\u00a0D, Lally\u00a0BE, Morcos\u00a0JJ, Heros\u00a0RC, Komotar\u00a0RJ (2013) The role of radiosurgery to the tumor bed after resection of brain metastases. Neurosurgery 72:317\u2013325","journal-title":"Neurosurgery"},{"key":"2123_CR30","doi-asserted-by":"publisher","first-page":"854402","DOI":"10.3389\/fonc.2022.854402","volume":"12","author":"S Rubino","year":"2022","unstructured":"Rubino\u00a0S, Oliver\u00a0DE, Tran\u00a0ND, Vogelbaum\u00a0MA, Forsyth\u00a0PA, H\u2011HM YAK, Etame\u00a0AB (2022) Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Front Oncol 12:854402. https:\/\/doi.org\/10.3389\/fonc.2022.854402","journal-title":"Front Oncol"},{"key":"2123_CR31","doi-asserted-by":"publisher","first-page":"3038047","DOI":"10.21037\/apm-20-605","volume":"9","author":"N Wang","year":"2020","unstructured":"Wang\u00a0N, Zhang\u00a0Y, Mi\u00a0Y, Deng\u00a0H, Chen\u00a0G, Tang\u00a0Z, Mao\u00a0J, Cui\u00a0S, Zhang\u00a0Y, Wang\u00a0L (2020) Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a\u00a0meta-analysis and systematic review. Ann Palliat Med 9:3038047\u20133033047. https:\/\/doi.org\/10.21037\/apm-20-605","journal-title":"Ann Palliat Med"},{"key":"2123_CR32","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","volume":"34","author":"BJ Solomon","year":"2016","unstructured":"Solomon\u00a0BJ, Cappuzzo\u00a0F, Felip\u00a0E, Blackhall\u00a0FH, Costa\u00a0DB, Kim\u00a0D\u2011W, Nakagawa\u00a0K, Wu\u00a0Y\u2011L, Mekhail\u00a0T, Paolini\u00a0J, Tursi\u00a0J, Usari\u00a0T, Wilner\u00a0KD, Selaru\u00a0P, Mok\u00a0TSK (2016) J Clin Oncol Off J Am Soc Clin Oncol. Intracranial Efficacy Crizotinib Versus Chemother Patients With Adv Alk-positive Non-small-cell Lung Cancer: Results From Profile 1014 34:2858\u20132865. https:\/\/doi.org\/10.1200\/JCO.2015.63.5888","journal-title":"Intracranial Efficacy Crizotinib Versus Chemother Patients With Adv Alk-positive Non-small-cell Lung Cancer: Results From Profile 1014"},{"key":"2123_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang\u00a0JCH, Kim\u00a0S\u2011W, Kim\u00a0D\u2011W, Lee\u00a0J\u2011S, Cho\u00a0BC, Ahn\u00a0J\u2011S, Lee\u00a0DH, Kim\u00a0TM, Goldman\u00a0JW, Natale\u00a0RB, Brown\u00a0AP, Collins\u00a0B, Chmielecki\u00a0J, Vishwanathan\u00a0K, Mendoza-Naranjo\u00a0A, Ahn\u00a0M\u2011J (2020) Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation\u2013Positive Non\u2013Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J\u00a0Clin Oncol 38:538\u2013547. https:\/\/doi.org\/10.1200\/JCO.19.00457","journal-title":"J Clin Oncol"},{"key":"2123_CR34","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana\u00a0T, Nakagawa\u00a0K, Cho\u00a0BC, Cobo\u00a0M, Cho\u00a0EK, Bertolini\u00a0A, Bohnet\u00a0S, Zhou\u00a0C, Lee\u00a0KH, Nogami\u00a0N, Okamoto\u00a0I, Leighl\u00a0N, Hodge\u00a0R, McKeown\u00a0A, Brown\u00a0AP, Rukazenkov\u00a0Y, Ramalingam\u00a0SS, Vansteenkiste\u00a0J (2018) CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer. J\u00a0Clin Oncol 36:3290\u20133297. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol"},{"key":"2123_CR35","doi-asserted-by":"publisher","first-page":"175883591879758","DOI":"10.1177\/1758835918797589","volume":"10","author":"P-L Su","year":"2018","unstructured":"Su\u00a0P\u2011L, Wu\u00a0Y\u2011L, Chang\u00a0W\u2011Y, Ho\u00a0C\u2011L, Tseng\u00a0Y\u2011L, Lai\u00a0W\u2011W, Su\u00a0W\u2011C, Lin\u00a0C\u2011C, Yang\u00a0S\u2011C (2018) Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol 10:1758835918797589. https:\/\/doi.org\/10.1177\/1758835918797589","journal-title":"Ther Adv Med Oncol"},{"key":"2123_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi\u00a0F, Mazieres\u00a0J, Merlio\u00a0J\u2011P, Debieuvre\u00a0D, Mosser\u00a0J, Lena\u00a0H, Ouafik\u00a0L, Besse\u00a0B, Rouquette\u00a0I, Westeel\u00a0V, Escande\u00a0F, Monnet\u00a0I, Lemoine\u00a0A, Veillon\u00a0R, Blons\u00a0H, Audigier-Valette\u00a0C, Bringuier\u00a0P\u2011P, Lamy\u00a0R, Beau-Faller\u00a0M, Pujol\u00a0J\u2011L, Sabourin\u00a0J\u2011C, Penault-Llorca\u00a0F, Denis\u00a0MG, Lantuejoul\u00a0S, Morin\u00a0F, Tran\u00a0Q, Missy\u00a0P, Langlais\u00a0A, Milleron\u00a0B, Cadranel\u00a0J, Soria\u00a0J\u2011C, Zalcman\u00a0G, contributors\u00a0BF (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a\u00a01-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet Lond Engl 387:1415\u20131426. https:\/\/doi.org\/10.1016\/S0140-6736(16)00004-0","journal-title":"Lancet Lond Engl"},{"key":"2123_CR37","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun\u00a0E, Guckenberger\u00a0M, Smits\u00a0M, Dummer\u00a0R, Bachelot\u00a0T, Sahm\u00a0F, Galldiks\u00a0N, de Azambuja\u00a0E, Berghoff\u00a0AS, Metellus\u00a0P, Peters\u00a0S, Hong\u00a0Y\u2011K, Winkler\u00a0F, Schadendorf\u00a0D, van den Bent\u00a0M, Seoane\u00a0J, Stahel\u00a0R, Minniti\u00a0G, Wesseling\u00a0P, Weller\u00a0M, Preusser\u00a0M (2021) EANO\u2014ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32:1332\u20131347. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.016","journal-title":"Ann Oncol"},{"key":"2123_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi\u00a0HA, Forsyth\u00a0PA, Algazi\u00a0A, Hamid\u00a0O, Hodi\u00a0SF, Moschos\u00a0SJ, Khushalani\u00a0NI, Lewis\u00a0K, Lao\u00a0CD, Postow\u00a0MA, Atkins\u00a0MB, Ernstoff\u00a0MS, Reardon\u00a0DA, Puzanov\u00a0I, Kudchadkar\u00a0RR, Thomas\u00a0RP, Tarhini\u00a0A, Pavlick\u00a0AC, Jiang\u00a0J, Avila\u00a0A, Demelo\u00a0S, Margolin\u00a0K (2018) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N\u00a0Engl J Med 379:722\u2013730. https:\/\/doi.org\/10.1056\/NEJMoa1805453","journal-title":"N Engl J Med"},{"key":"2123_CR39","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","volume":"39","author":"GV Long","year":"2021","unstructured":"Long\u00a0GV, Atkinson\u00a0V, Lo\u00a0S, Guminski\u00a0AD, Sandhu\u00a0SK, Brown\u00a0MP, Gonzalez\u00a0M, Scolyer\u00a0RA, Emmett\u00a0L, McArthur\u00a0GA, Menzies\u00a0AM (2021) Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2\u00a0study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J\u00a0Clin Oncol 39:9508\u20139508. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9508","journal-title":"J Clin Oncol"},{"key":"2123_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/CMR.0000000000000816","volume":"32","author":"S Pedersen","year":"2022","unstructured":"Pedersen\u00a0S, M\u00f8ller\u00a0S, Donia\u00a0M, Persson\u00a0GF, Svane\u00a0IM, Ellebaek\u00a0E (2022) Real-world data on melanoma brain metastases and survival outcome. Melanoma Res 32:173\u2013182. https:\/\/doi.org\/10.1097\/CMR.0000000000000816","journal-title":"Melanoma Res"},{"key":"2123_CR41","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/cancers12061640","volume":"12","author":"P Becco","year":"2020","unstructured":"Becco\u00a0P, Gallo\u00a0S, Poletto\u00a0S, Frascione\u00a0MPM, Crotto\u00a0L, Zaccagna\u00a0A, Paruzzo\u00a0L, Caravelli\u00a0D, Carnevale-Schianca\u00a0F, Aglietta\u00a0M (2020) Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers 12:1640. https:\/\/doi.org\/10.3390\/cancers12061640","journal-title":"Cancers"},{"key":"2123_CR42","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3390\/cancers13122927","volume":"13","author":"A Garcia-Alvarez","year":"2021","unstructured":"Garcia-Alvarez\u00a0A, Papakonstantinou\u00a0A, Oliveira\u00a0M (2021) Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers. Brain 13:2927. https:\/\/doi.org\/10.3390\/cancers13122927","journal-title":"Brain"},{"key":"2123_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1186\/s12885-021-08708-5","volume":"21","author":"MD Hackshaw","year":"2021","unstructured":"Hackshaw\u00a0MD, Danysh\u00a0HE, Henderson\u00a0M, Wang\u00a0E, Tu\u00a0N, Islam\u00a0Z, Ladner\u00a0A, Ritchey\u00a0ME, Salas\u00a0M (2021) Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a\u00a0systematic literature review. Bmc Cancer 21:967. https:\/\/doi.org\/10.1186\/s12885-021-08708-5","journal-title":"Bmc Cancer"},{"key":"2123_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy\u00a0RK, Loi\u00a0S, Okines\u00a0A, Paplomata\u00a0E, Hamilton\u00a0E, Hurvitz\u00a0SA, Lin\u00a0NU, Borges\u00a0V, Abramson\u00a0V, Anders\u00a0C, Bedard\u00a0PL, Oliveira\u00a0M, Jakobsen\u00a0E, Bachelot\u00a0T, Shachar\u00a0SS, M\u00fcller\u00a0V, Braga\u00a0S, Duhoux\u00a0FP, Greil\u00a0R, Cameron\u00a0D, Carey\u00a0LA, Curigliano\u00a0G, Gelmon\u00a0K, Hortobagyi\u00a0G, Krop\u00a0I, Loibl\u00a0S, Pegram\u00a0M, Slamon\u00a0D, Palanca-Wessels\u00a0MC, Walker\u00a0L, Feng\u00a0W, Winer\u00a0EP (2020) Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N\u00a0Engl J Med 382:597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"},{"key":"2123_CR45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s\u00a0J, Kim\u00a0S\u2011B, Chung\u00a0W\u2011P, Im\u00a0S\u2011A, Park\u00a0YH, Hegg\u00a0R, Kim\u00a0MH, Tseng\u00a0L\u2011M, Petry\u00a0V, Chung\u00a0C\u2011F, Iwata\u00a0H, Hamilton\u00a0E, Curigliano\u00a0G, Xu\u00a0B, Huang\u00a0C\u2011S, Kim\u00a0JH, Chiu\u00a0JWY, Pedrini\u00a0JL, Lee\u00a0C, Liu\u00a0Y, Cathcart\u00a0J, Bako\u00a0E, Verma\u00a0S, Hurvitz\u00a0SA (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N\u00a0Engl J Med 386:1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"2123_CR46","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","volume":"28","author":"R Bartsch","year":"2022","unstructured":"Bartsch\u00a0R, Berghoff\u00a0AS, Furtner\u00a0J, Marhold\u00a0M, Bergen\u00a0ES, Roider-Schur\u00a0S, Starzer\u00a0AM, Forstner\u00a0H, Rottenmanner\u00a0B, Dieckmann\u00a0K, Bago-Horvath\u00a0Z, Haslacher\u00a0H, Widhalm\u00a0G, Ilhan-Mutlu\u00a0A, Minichsdorfer\u00a0C, Fuereder\u00a0T, Szekeres\u00a0T, Oehler\u00a0L, Gruenberger\u00a0B, Singer\u00a0CF, Weltermann\u00a0A, Puhr\u00a0R, Preusser\u00a0M (2022) Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a\u00a0single-arm, phase 2\u00a0trial. Nat Med 28:1840\u20131847. https:\/\/doi.org\/10.1038\/s41591-022-01935-8","journal-title":"Nat Med"},{"key":"2123_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi\u00a0S, Jacot\u00a0W, Yamashita\u00a0T, Sohn\u00a0J, Vidal\u00a0M, Tokunaga\u00a0E, Tsurutani\u00a0J, Ueno\u00a0NT, Prat\u00a0A, Chae\u00a0YS, Lee\u00a0KS, Niikura\u00a0N, Park\u00a0YH, Xu\u00a0B, Wang\u00a0X, Gil-Gil\u00a0M, Li\u00a0W, Pierga\u00a0J\u2011Y, Im\u00a0S\u2011A, Moore\u00a0HCF, Rugo\u00a0HS, Yerushalmi\u00a0R, Zagouri\u00a0F, Gombos\u00a0A, Kim\u00a0S\u2011B, Liu\u00a0Q, Luo\u00a0T, Saura\u00a0C, Schmid\u00a0P, Sun\u00a0T, Gambhire\u00a0D, Yung\u00a0L, Wang\u00a0Y, Singh\u00a0J, Vitazka\u00a0P, Meinhardt\u00a0G, Harbeck\u00a0N, Cameron\u00a0DA (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N\u00a0Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"2123_CR48","first-page":"285","volume":"5","author":"MC LeCompte","year":"2018","unstructured":"LeCompte\u00a0MC, McTyre\u00a0ER, Strowd\u00a0RE, Lanier\u00a0C, Soike\u00a0MH, Hughes\u00a0RT, Masters\u00a0AH, Cramer\u00a0CK, Farris\u00a0M, Ruiz\u00a0J, Watabe\u00a0K, Laxton\u00a0AW, Tatter\u00a0SB, Winkfield\u00a0KM, Chan\u00a0MD (2018) Impact of diabetes mellitus on outcomes in patients with brain metastasis treated with stereotactic radiosurgery. J\u00a0Radiosurgery Sbrt 5:285\u2013291","journal-title":"J Radiosurgery Sbrt"},{"key":"2123_CR49","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria\u00a0A, Togawa\u00a0K, Mohile\u00a0SG, Owusu\u00a0C, Klepin\u00a0HD, Gross\u00a0CP, Lichtman\u00a0SM, Gajra\u00a0A, Bhatia\u00a0S, Katheria\u00a0V, Klapper\u00a0S, Hansen\u00a0K, Ramani\u00a0R, Lachs\u00a0M, Wong\u00a0FL, Tew\u00a0WP (2011) Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J\u00a0Clin Oncol 29:3457\u20133465. https:\/\/doi.org\/10.1200\/JCO.2011.34.7625","journal-title":"J Clin Oncol"},{"key":"2123_CR50","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera\u00a0CA, Rainfray\u00a0M, Mathoulin-P\u00e9lissier\u00a0S, Mertens\u00a0C, Delva\u00a0F, Fonck\u00a0M, Soubeyran\u00a0PL (2012) Screening older cancer patients: first evaluation of the G\u20118 geriatric screening tool. Ann Oncol 23:2166\u20132172. https:\/\/doi.org\/10.1093\/annonc\/mdr587","journal-title":"Ann Oncol"},{"key":"2123_CR51","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.3390\/cancers13133353","volume":"13","author":"I Ilic","year":"2021","unstructured":"Ilic\u00a0I, Faron\u00a0A, Heimann\u00a0M, Potthoff\u00a0A\u2011L, Sch\u00e4fer\u00a0N, Bode\u00a0C, Borger\u00a0V, Eichhorn\u00a0L, Giordano\u00a0FA, G\u00fcresir\u00a0E, Jacobs\u00a0AH, Ko\u00a0Y\u2011D, Landsberg\u00a0J, Lehmann\u00a0F, Radbruch\u00a0A, Herrlinger\u00a0U, Vatter\u00a0H, Schuss\u00a0P, Schneider\u00a0M (2021) Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. Cancers 13:3353. https:\/\/doi.org\/10.3390\/cancers13133353","journal-title":"Cancers"},{"key":"2123_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-018-2948-8","volume":"140","author":"J Furtner","year":"2018","unstructured":"Furtner\u00a0J, Berghoff\u00a0AS, Sch\u00f6pf\u00a0V, Reumann\u00a0R, Pascher\u00a0B, Woitek\u00a0R, Asenbaum\u00a0U, Pelster\u00a0S, Leitner\u00a0J, Widhalm\u00a0G, Gatterbauer\u00a0B, Dieckmann\u00a0K, H\u00f6ller\u00a0C, Prayer\u00a0D, Preusser\u00a0M (2018) Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases. J\u00a0Neurooncol 140:173\u2013178. https:\/\/doi.org\/10.1007\/s11060-018-2948-8","journal-title":"J Neurooncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02123-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02123-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T16:02:32Z","timestamp":1711468952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02123-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2123"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02123-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.\u00a0H.\u00a0Nicolay has received research grants from Novocure and speaker honoraria from Merck. C.\u00a0Seidel has received speaker and\/or advisory board honoraria from AbbVie, Bristol-Myers Squibb, HRA Pharma, Medac, Novocure, Roche, Seagen. M.\u00a0H\u00fcgel, J.\u00a0St\u00f6hr, T.\u00a0Kuhnt, F.\u00a0N\u00e4gler, K.\u00a0Papsdorf, S.\u00a0Klagges, P.\u00a0Hambsch and E.\u00a0G\u00fcresir declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}